Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19149542 | 0.87 | LMNA (0.56) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13613923 | 0.84 | LMNA (0.73) | LMNAALDH1A1MEN1KMT2ARAD52 | |
| SCHEMBL19148495 | 0.83 | LMNA (0.70) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2948683 | 0.83 | POLB (0.54) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1352813 | 0.82 | GRIN2D (0.75) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1937745 | 0.81 | GRIN2D (0.55) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL19150630 | 0.80 | GRIN2D (0.55) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13483181 | 0.80 | GRIN2D (0.54) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4713929 | 0.80 | GRIN2D (0.54) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27163493 | 0.78 | ALDH1A1 (0.42) | LMNAALDH1A1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | LMNA 867/4885ALDH1A1 652/4885GRIN2D 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.